← Back to Search

mNSCLC - 1st Line of Therapy for Lung Cancer

N/A
Waitlist Available
Research Sponsored by Daiichi Sankyo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to end of follow-up or death, whichever comes first, up to approximately 40 months.
Awards & highlights

Summary

This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.

Eligible Conditions
  • Cancer
  • Lung Cancer
  • Non-Small Cell Lung Cancer
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to end of follow-up or death, whichever comes first, up to approximately 40 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to end of follow-up or death, whichever comes first, up to approximately 40 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Survival (OS) of (AGA+/-) mNSCLC Participant With And Without Brain Metastases by Line of Therapy

Trial Design

4Treatment groups
Experimental Treatment
Group I: mNSCLC - OverallExperimental Treatment1 Intervention
Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023)
Group II: mNSCLC - 3rd Line of TherapyExperimental Treatment1 Intervention
Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023) treated with systemic anti-cancer therapy in third line setting.
Group III: mNSCLC - 2nd Line of TherapyExperimental Treatment1 Intervention
Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023) treated with systemic anti-cancer therapy in second line setting.
Group IV: mNSCLC - 1st Line of TherapyExperimental Treatment1 Intervention
Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023) treated with systemic anti-cancer therapy in first line setting.

Find a Location

Who is running the clinical trial?

Daiichi SankyoLead Sponsor
401 Previous Clinical Trials
424,543 Total Patients Enrolled
~15011 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top